Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
The state-of-the-art facility provides a pathway from development to large-scale biologics production
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe Covid-19
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The facility is expected to be completed in 2024
Subscribe To Our Newsletter & Stay Updated
